Tonix Pharmaceuticals stock halted ahead of FDA approval news
Angela M. Cacace, the Chief Scientific Officer of Arvinas, Inc. (NASDAQ:ARVN), recently sold shares of the company’s common stock, according to a filing with the Securities and Exchange Commission. On February 24, Cacace sold a total of 4,207 shares, generating proceeds of $70,238. The shares were sold at prices ranging from $16.55 to $16.75 per share, near the stock’s 52-week low of $16.07. The transaction comes as the stock has declined over 10% in the past week, though InvestingPro analysis suggests the company remains undervalued.
These transactions were executed to cover tax withholding obligations related to the vesting and settlement of restricted stock units (RSUs) granted in previous years. The $1.17 billion market cap company maintains a strong balance sheet, with more cash than debt and a healthy current ratio of 4.64. Following these sales, Cacace retains ownership of 97,231 shares in Arvinas. For deeper insights into ARVN’s valuation and financial health, check out the comprehensive research report available on InvestingPro.
In other recent news, Arvinas Inc. reported its fourth-quarter 2024 earnings, revealing a smaller-than-expected loss per share with an EPS of -$0.63, beating the forecasted -$0.96. However, the company’s revenue of $59.2 million fell short of the anticipated $62.67 million. Despite this revenue miss, Arvinas maintains a strong financial position with over $1 billion in cash, supporting operations into 2027. Analysts have mixed views on the company’s stock, with UBS maintaining a Buy rating and a $74 price target, while Stifel and H.C. Wainwright have reduced their price targets to $51 and $81, respectively, but also maintain Buy ratings. BMO Capital Markets adjusted its price target to $82, retaining an Outperform rating, citing confidence in the company’s financial health and upcoming clinical data. Arvinas is closely watched for the upcoming VERITAC-2 Phase 3 trial results in breast cancer treatment, which could significantly impact future revenue. The company’s strategic approach to data release and presentation is aimed at maximizing the impact of the study results.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.